HOME >> MEDICINE >> NEWS
Chemotherapy options improve for patients with advanced colorectal cancer

For the first time, researchers have shown that a chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) is as safe and effective as infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) in the first-line treatment of metastatic colorectal carcinoma (MCRC). The findings are reported today at the 2nd ESMO Scientific & Educational Conference (ESEC) in Budapest, Hungary.

"We conducted this phase III study because the combination of oral capecitabine and oxaliplatin showed promising effects in different phase II studies. The idea of this study was to look whether CAPOX can replace the standard treatment of iv. 5-FU/folinic acid in patients with MCRC", said lead author Dr. Hendrik-Tobias Arkenau, from Clinic Bremen East in Germany.

From 2002 to 2004, the authors randomly assigned 476 patients who had not undergone previous chemotherapy to receive either FUFOX (5-fluorouracil (5-FU) 2000mg/m 24h infusion, folinic acid 500mg/m, oxaliplatin 50mg/m d1,8,15,22; q5 wks) or CAPOX (capecitabine 1000mg/m bid d1-14, oxaliplatin 70mg/m d1 and 8; q3 wks).

So far, based on an analysis of 2541 treatment cycles (1026 FUFOX, 1515 CAPOX), both regimens are comparably toxic and showed similar response rates (ITT-RR: 50% FUFOX and 47% CAPOX, p=NS).

Median length of time without progression of disease was 34.7 weeks in the FUFOX arm and 30.3 weeks in the CAPOX arm, respectively, a difference that was not statistically different (p=0.1), the authors found. Additionally, both treatment arms showed similar overall survival, FUFOX 74.9 weeks and CAPOX 70.9 weeks, p=0.72.

The authors conclude that CAPOX shows comparable efficacy and toxicity profiles compared to the FUFOX regimen in patients chemonaive MCRC.

"This study is important for patients because the CAPOX regimen is more convenient to administer. Patients will appreciate needing to come only twice in three weeks as outpatients to receive the 2 hourly oxaliplatin dose. Esp
'"/>

Contact: Gracemarie Bricalli
gracemarie@esmo.org
41-91-973-1911
European Society for Medical Oncology
6-Jun-2005


Page: 1 2

Related medicine news :

1. Chemotherapy with bevacizumab increases risk of blood clots in arteries
2. Chemotherapy may enhance the effectiveness of brain tumor vaccines
3. Chemotherapy more effective when given before breast cancer surgery
4. Chemotherapy temporarily affects the structures of the human brain
5. Chemotherapy gel may fight breast cancer and reduce breast deformity
6. Chemotherapy given directly to the liver improves survival for patients with colorectal cancer
7. Chemotherapy after surgery extends survival for patients with advanced endometrial cancer
8. Chemotherapy errors rare, but have potential for serious consequences
9. Chemotherapy for brain tumors is boosted after vaccine targets resistance-related antigen
10. Asthma study shows patients have more options to control disease
11. Study sheds light on medication treatment options for bipolar disorder

Post Your Comments:
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... One of ... interviews to discuss his new book, The Pain Antidote , which provides strategies ... of Las Vegas Recovery Center’s Chronic Pain Treatment Program, wrote the book in conjunction ...
(Date:8/4/2015)... ... 04, 2015 , ... 24/7 Care At Home , a provider of ... today announced that the U.S. Department of Veteran’s Affairs (VA) has awarded its agency ... is well on the path to meeting the aspirational goals the VA promotes each ...
(Date:8/4/2015)... ... 04, 2015 , ... Increasingly, patients are researching online to ... In an effort to share more and better information with these savvy and ... share patient satisfaction ratings and comments about its doctors and advanced practice providers. ...
(Date:8/4/2015)... ... August 04, 2015 , ... SanusEO, the healthcare industry ... its executive leadership team as Senior Vice President of Sales and Marketing. Mr. ... expanding global markets with a special emphasis on the healthcare industry. , Today, ...
(Date:8/4/2015)... NJ (PRWEB) , ... August 04, 2015 , ... Montclair ... Arts and Health, the first of its kind in New Jersey, which starting this ... of the Arts and Graduate School partnered with Atlantic Health System, one of the ...
Breaking Medicine News(10 mins):Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3
(Date:8/4/2015)... Young Innovations ("Young"), a leading global ... the acquisition of the professional dental contract manufacturing ... MPL PDCMD manufactures fluoride varnish, prophy paste and ... procedures. "This acquisition marks the ... high-growth segments," said Dave Sproat , CEO ...
(Date:8/4/2015)... , Aug. 4, 2015  Rigel Pharmaceuticals, Inc. (Nasdaq: ... second quarter and six months ended June 30, 2015. ... in ITP are progressing and we continue to expect ... Rodriguez , president and chief executive officer of Rigel. ... other clinical programs, including evaluating fostamatinib for new treatment ...
(Date:8/4/2015)... SEATTLE , Aug. 4, 2015  Dr. ... Institute states the potential FDA approval of flibanserin, ... sets women and the treatment of decreased female ... women has many root causes and addressing libido ... is dangerous. ...
Breaking Medicine Technology:Young Innovations Announces Acquisition of Medical Products Laboratories' Professional Dental Contract Manufacturing Division 2Rigel Announces Second Quarter 2015 Financial Results 2Rigel Announces Second Quarter 2015 Financial Results 3Rigel Announces Second Quarter 2015 Financial Results 4Rigel Announces Second Quarter 2015 Financial Results 5Rigel Announces Second Quarter 2015 Financial Results 6Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5
Cached News: